Ceva’s spironolactone shows benefits as canine heart failure therapy

Ceva Animal Health has announced the publication of new clinical data that underlines the benefits of spironolactone for the management of heart failure in dogs.

Data published in the Journal of Veterinary Internal Medicine has assessed the advantages of using spironolactone alongside conventional therapy, such as an ACE inhibitor and furosemide, in the treatment of this disease.

It revealed that this therapy approach leads to a significant reduction in the number of deaths due to cardiac disease and/or renal disease, without the associated increase in hyperkalaemia risk seen in humans.

Fraser Broadfoot, small animal product manager at Ceva Animal Health, said: "This publication further highlights the benefits and safety of using spironolactone alongside an ACEi as part of first-line therapy for canine heart failure."

The manufacturer is responsible for the creation of the product Cardalis, which contains the leading ACEi benazepril and spironolactone at their standard dose in a single convenient tablet.

Ceva recently organised a series of free interactive cardiology webinars to discuss the issue of managing heart failure with animal health professionals, while highlighting the benefits of Cardalis.